Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients

Basit Öğe Kaydı
dc.authorid0000-0003-4304-9245
dc.authorid0000-0002-3285-417X
dc.authorscopusid57189243089
dc.authorscopusid56545735000
dc.authorscopusid57212584643
dc.authorscopusid36456321300
dc.authorscopusid56370690600
dc.authorscopusid14022986200
dc.authorscopusid37115534400
dc.authorwosidBaşcı, Semih/AAB-4823-2021
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.contributor.authorYigenoğlu, Tuğçe Nur
dc.contributor.authorBaşçı, Semih
dc.contributor.authorŞahin, Derya
dc.contributor.authorUlaş, Turgay
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:40:01Z
dc.date.available2022-05-11T14:40:01Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractSARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.
dc.identifier.doi10.1016/j.transci.2021.103237
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue6en_US
dc.identifier.pmid34419356
dc.identifier.scopus2-s2.0-85113813802
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103237
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8836
dc.identifier.volume60
dc.identifier.wosWOS:000733239700018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMesenchymal stem cell
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectTransfusion
dc.subjectTransplantation
dc.subjectStromal Cells
dc.subjectTissue Factor
dc.subjectHla-G
dc.subjectTherapy
dc.subjectTransplantation
dc.subjectAce2
dc.titleMesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8836.pdf
Boyut:
770.41 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu